16:00 EDT Aravive trading halted, news pending
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARAV:
- Aravive (NASDAQ:ARAV) Plummets On Phase 3 Disappointment In Ovarian Cancer
- Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023
- Aravive management to meet virtually with Cantor Fitzgerald
- Aravive to Participate in William Blair’s Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023
- Aravive price target lowered to $9 from $12 at BTIG
Questions or Comments about the article? Write to editor@tipranks.com